- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 01.04. | Journey Medical appoints Ramsey Alloush as COO | 1 | Seeking Alpha | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 01.04. | Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer | 55 | GlobeNewswire (Europe) | SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses... ► Artikel lesen | |
| 01.04. | Journey Medical appoints new COO amid growth phase | 2 | Investing.com | ||
| 26.03. | Journey Medical GAAP EPS of -$0.72 beats by $0.44, revenue of $56.13M misses by $0.59M | 4 | Seeking Alpha | ||
| 26.03. | Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights | 606 | GlobeNewswire (Europe) | FDA Approval of Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended... ► Artikel lesen | |
| 24.03. | Journey Medical Corporation Launches Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea | 3 | GlobeNewswire (USA) | ||
| 24.03. | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 19.03. | Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 | 3 | GlobeNewswire (USA) | ||
| 05.03. | FDA approves new rosacea treatment from Journey Medical | 2 | Investing.com | ||
| 04.03. | Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida | 1 | GlobeNewswire (USA) | ||
| 20.02. | Journey Medical Corporation (DERM): A Bull Case Theory | 1 | Insider Monkey | ||
| 05.02. | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 24.01. | Minot Light Capital's Largest Performance Detractor in Q4: Journey Medical (DERM) | 2 | Insider Monkey | ||
| 13.11.24 | Journey Medical GAAP EPS of -$0.12 beats by $0.03, revenue of $14.63M beats by $0.24M | 1 | Seeking Alpha | ||
| 12.11.24 | Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights | 159 | GlobeNewswire (Europe) | U.S. FDA approved Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025... ► Artikel lesen | |
| 12.11.24 | Journey Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.24 | FDA approves Journey Medical's Emrosi to treat inflammatory lesions of rosacea | - | PMLiVE | ||
| 05.11.24 | FDA approves Journey Medical's rosacea treatment Emrosi | 1 | Pharmaceutical Technology | ||
| 04.11.24 | Journey Medical, with FDA nod, won't stop believing it can establish new rosacea standard of care | 3 | FiercePharma |
Seite:
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 20,690 | -0,24 % | Investor Woche: Börsencrash durch Trumps Zollhammer, Magnificent 7, Berkshire Hathaway, Anheuser Busch, EON, Allianz, Pfizer | Trumps Zollhammer lässt die Aktienmärkte weltweit abstürzen. Besonders betroffen: Die Magnificent 7. Warren Buffetts hohe Cash-Reserven könnten Berkshire Hathaway zugutekommen. Unternehmen mit geringer... ► Artikel lesen | |
| GILEAD SCIENCES | 97,60 | +0,96 % | Gilead Sciences: The Global Health Challenge of HIV and Hepatitis B Coinfections | NORTHAMPTON, MA / ACCESS Newswire / April 8, 2025 / In 2019, Somchai, a Thai native, was 21 years old and faced a double threat to his long-term health and wellbeing. He was living with hepatitis B... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 438,95 | +0,94 % | Vertex Gains European Approval For Expanded Use Of KAFTRIO In Treating Cystic Fibrosis | CAMBRIDGE (MASSACHUSETTS) (dpa-AFX) - Vertex Pharmaceuticals (VRTX) announced that the European Commission has approved a label expansion for KAFTRIO (ivacaftor/tezacaftor/elexacaftor) in combination... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 4,037 | -4,54 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 4,100 | -0,49 % | Astria Therapeutics, Inc.: Astria Therapeutics beginnt Phase-3-Zulassungsstudie ALPHA-ORBIT zu Navenibart bei hereditärem Angioödem | -- Studie zum Nachweis der Wirksamkeit und Sicherheit der Verabreichung alle 3 und alle 6 Monate in einem 6-monatigen Behandlungszeitraum --
Astria Therapeutics, Inc. (Nasdaq: ATXS), ein biopharmazeutisches... ► Artikel lesen | |
| ROCKET LAB USA | 17,490 | +8,93 % | Rocket Lab's Neutron-Rakete: Neue Perspektiven für die US Space Force | ||
| OPKO HEALTH | 1,392 | -0,32 % | H.C. Wainwright maintains $3 target, Buy on Opko Health stock | ||
| LIGAND PHARMACEUTICALS | 90,00 | -1,64 % | ROUNDUP: Ligand Pharma Slips To Loss In Q4; Confirms FY25 Outlook | WASHINGTON (dpa-AFX) - Biopharmaceutical company Ligand Pharmaceuticals, Inc. (LGND), while reporting a loss in its fourth quarter, compared to prior year's profit, on Thursday confirmed fiscal... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 100,35 | +2,46 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference | DUBLIN, March 26, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 24th Annual Needham Healthcare Conference. Company... ► Artikel lesen | |
| ROYALTY PHARMA | 28,960 | +1,79 % | Dividendenbekanntmachungen (21.02.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABRDN AUSTRALIA EQUITY FUND INC US0030111035 0,12 USD 0,1143 EUR ABRDN JAPAN EQUITY FUND INC US00306J1097 0,11 USD 0,1047 EUR ANGEL... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,640 | +3,23 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Announces Health Canada's Acceptance of AGAMREE New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals | CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing... ► Artikel lesen | |
| TG THERAPEUTICS | 34,815 | +2,13 % | TG Therapeutics präsentiert BRIUMVI-Daten auf Neurologiekonferenz | ||
| CORBUS PHARMACEUTICALS | 4,940 | +3,35 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity | CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled... ► Artikel lesen | |
| CATALENT | 59,93 | 0,00 % | Ardena Holding NV.: Ardena Completes Acquisition of Advanced Drug Product Manufacturing Facility from Catalent and Expands Bioanalytical Services in North America | Ghent, Belgium, 4th February 2025
Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO) and bioanalytical Contract Research Organization (CRO) with facilities... ► Artikel lesen | |
| TALPHERA | 0,456 | -0,76 % | H.C. Wainwright maintains Buy on Talphera stock, $6 target |
JOURNEY MEDICAL CORPORATION gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 6,935 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.
